Objective: To evaluate the need and the magnitude of Levothyroxine (LT4) increase in hypothyroid pregnant women on liquid compared to tablet formulations.
INTRODUCTION
Hypothyroidism in pregnancy is defined as TSH above the trimester-specific reference range and is subdivided in subclinical or overt, depending on FT4 values within or below the normal range, respectively. Current Guidelines suggest to adopt local trimester specific range for TSH, and in absence of this, to consider an upper limit of 2.5mIU/L in the first, 3 .0 mIU/L in the second and 3.0-3.5 mIU\L in the third trimester [1] [2] [3] [4] . The state of pregnancy requires an adaptation of thyroid function that results physiologically increased [5] . That is the reason why hypothyroid women on replacement treatment with Levothyroxine (LT4), usually require an increase of LT4 amount by 30-50% at the beginning of pregnancy [6] . The need and the magnitude of LT4 increase depend on the etiology of hypothyroidism and the pre-pregnancy TSH level [7, 8] . Traditionally, LT4 is administered in form of tablet, but soft gel capsule or liquid formulations are available in some European Countries. Recent studies have shown a better absorption of soft gel\liquid formulation than tablet, hesitating in more stable TSH values [9] [10] [11] . The aim of the study is to retrospectively evaluate the need and the magnitude of LT4 increase in hypothyroid pregnant women on liquid compared to tablet formulation.
SUBJECTS AND METHODS:
Women were recruited by searching the database of patients treated and followed at the Thyroid Unit of the Department of Clinical and Experimental Science, University of Brescia.
The search criteria were as follows: a) pregnant women on treatment for hypothyroidism (both liquid or tablet LT4) who have given birth at our hospital between February 2012 and January 2014; b) TSH and FT4 level obtained at least three months before missed menstrual cycle, with a TSH value less than 2.5 mIU\L; c) TSH and FT4 obtained within 12 weeks of pregnancy, and each month subsequently; d) detailed LT4 treatment; e) detailed other drugs therapy (if any). As per protocol adopted in our Institution, in case of TSH higher than the pregnancy specific reference range, LT4 was increased by 25µg/day at each visit. All women satisfying the above criteria were enrolled in this study and informed consent was obtained from all subjects. 
Statistics
Statistical analysis was performed using SPSS 17.0 software (SPSS, Imnc, Evanston, IL, USA). Mann-Whitney U test was performed to evaluate TSH and FT4 distribution.
Comparisons between groups and difference between proportions were calculated using ANOVA test for quantitative variables, as appropriate. A logistic analysis was performed to examine the influence of confounders on the hormonal thyroid profile. Two-tailed p<0.05 was considered significant. Data are presented as mean ±standard deviation.
Results
Between February 2012 and January 2014, 31 hypothyroid pregnant who satisfied the above mentioned criteria gave birth at our hospital. All the subjects were nulliparous, and suffered from Hashimoto's thyroiditis. Fourteen patients were in replacement therapy with liquid LT4 and 17 were on tablet. Baseline demographics and clinical characteristics are shown in Table I There was no significant difference between women who needed to increase LT4 and those who did not (Table II) . There was no significant difference in parameters of newborn from mothers who needed to increase LT4 and those who did not (Table III) .
A logistic regression analysis taking into account age, pre-pregnancy and delivery weight, gestational weight gain, TSH values, showed that treatment with LT4 tablet was the only predictor of LT4 increase (OR 0.44, 95% CI 0.04-0.83; p=0.031).
Discussion
Either American or European Guidelines about treatment of thyroid disease in pregnancy suggest to treat hypothyroid women in order to keep TSH within trimester specific reference range [1] [2] [3] [4] . Increased TSH levels are associated with adverse events like miscarriage, gestational hypertension and preeclampsia, gestational diabetes, intrauterine growth restriction, neonatal low birth weight, reduced intelligence quotient in the offspring [12, 13] . Given the well known variation in demand of thyroid hormones during pregnancy, a prospective study demonstrated that in hypothyroid women, an increase of two tablet per week is able to maintain TSH within the pregnancy reference range, then mimicking the physiological adaptation of an healthy thyroid to the pregnant state [14] ; the need for an increase of LT4 dosage may be even higher than 30% in hypothyroidism induced by radioiodine or total thyroidectomy; other than the etiology of hypothyroidism, also the prepregnancy TSH level should be taken into account when deciding the variation dose: data suggest that increased LT4 dosage is necessary in 50% of cases when pre pregnancy TSH is 1.2-2.4 mIU\L versus 17% when TSH is lower than 1.2 mIU\L [7, 15, 16] .
In the present study that evaluated LT4 treatment in hypothyroid patients on liquid or tablet formulation we observed that, despite similar pre-pregnancy TSH levels (mean and distribution) the liquid-treated group require to increase the LT4 dose in a minority of cases. A possible explanation for this result may rely on the different characteristic of absorption demonstrated by the two formulations. Indeed, the gastric pH is one of the most important factors that influence the absorption of LT4, in an inversely proportional manner: the absorption capacity decreases with the increase of pH [17, 18] . Centanni et al. have demonstrated that patients with impaired acid secretion require an increase dose of thyroxine, confirming that normal acid gastric secretion is necessary for effective absorption of oral LT4 [19] . It is well known that during pregnancy gastric emptying and small intestine motility are reduced by 30-50% due to elevation of progesterone (20) (21) (22) . In addition, these changes alter bioavailability parameters like maximum concentration (Cmax) and time to maximum concentration (Tmax) of orally administered medication. The decrease in Cmax and increase in Tmax particularly affect medication taken daily as a single dose [23] . Another relevant modification during pregnancy is represented by an increase in gastric pH, due to a reduction of H + secretion and an increase in mucus production, which may increase the ionization of weak acids, tending to reduce their absorption more than that of weak bases [20, 21] . Many recent reports have clearly demonstrated that liquid LT4 formulation circumvents these problems, in patients taking proton pump inhibitors, those suffering from gastric related T4 malabsorption, those assuming T4 with coffee or fed by enteral tube, and also those submitted to bariatric surgery [24] [25] [26] [27] [28] . As our pregnant patients on tablet required to increase LT4 more often than those on liquid, it is possible that the usual increase in exogenous LT4 requirement may be partly due to altered LT4 tablet absorption and not exclusively to pregnancyrelated thyroid hormone increased demand. A major concern is represented by the alcohol content (243mg) that is present in vials of liquid formulation. As a matter of fact, current guidelines recommend abstinence from alcohol for women planning pregnancy, at conception, and during pregnancy [29, 30] . A recent meta-analysis did not find a significant increase in risk of low birth weight and small for gestational age for alcohol daily intake lower than 10 g, and risk of preterm birth for a daily intake lower than 18 g [31] . Our study as well did not find any difference between in characteristics of newborn from mother on liquid and tablet formulation.
In conclusion, although limited by the retrospective collection of data, and the small number of patients, results show that hypothyroid pregnant women on optimal replacement therapy before pregnancy, require increase of LT4 dose more often if on tablet than liquid formulation. Randomized prospective studies are necessary to confirm this preliminary finding, that may have relevant clinical implications in the treatment of hypothyroidsm in pregnancy.
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